R
RayThera
Breakthrough small molecule therapies addressing critical unmet needs in immunology
About RayThera
RayThera is a small molecule drug discovery company focused on developing therapies for immunological diseases with significant unmet medical needs. Founded in August 2023, the company leverages decades of drug discovery expertise to accelerate the development of safer and more effective therapeutics. RayThera operates in the pharmaceutical and biotechnology market, targeting healthcare providers and patients requiring advanced treatment options for immunological conditions. The business model centers on research and development, progressing from target identification to clinical trials, with revenue generated through partnerships, licensing agreements, and eventual product sales. The company's approach is characterized by a nimble and adaptable development process, ensuring rigorous standards are maintained throughout. RayThera collaborates with clinical trial partners to ensure compliance with global privacy and data protection regulations.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2023
- Headquarters
- San Diego, United States
- Open positions
- None listed
- Dealroom signal
- 54.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Inflammatory Diseases, Immune System, Biotech and Pharma, Small Molecules, DT and LS
- Business model
- Manufacturing
- Client focus
- b2b
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Jun 2026 | $0 | — | Biogen | ↗ |
| SERIES AOther financing | Apr 2025 | $110M | $440M | TTM Capital · OrbiMed · Foresite Capital | ↗ |
Growth signals
Latest recorded traffic for RayThera is 1.9K monthly website visits, up 3066.7% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
OrbiMed
Foresite Capital- TCTTM Capital
Other known investors1 additional known investor
Biogen
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about RayThera on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See RayThera’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.